Clopivas

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clopivas

Property Description
Active ingredient Clopidogrel (as Clopidogrel bisulfate)
Form Oral tablet (Film-coated tablet)
Pharmacological class Antiplatelet Agent / P2Y12 Inhibitor
Common use Prevention of blood clot formation
Origin Synthetic compound

1. Clopivas: Identity, Composition, and Unique Features

Clopivas is a prescription-only pharmaceutical preparation utilized for cardiovascular protection. Its core active ingredient is Clopidogrel (supplied as Clopidogrel bisulfate), a synthetic compound belonging to the thienopyridine-class of antiplatelets. The medicine is supplied as an oral tablet intended for systemic delivery.

The most distinctive pharmacological feature of Clopidogrel is its status as a prodrug; it is biologically inactive until it undergoes metabolic conversion within the liver. This prodrug characteristic is clinically recognized for influencing individual patient response. Clopivas is typically available as a single-ingredient product, positioning it as a key option for long-term antiplatelet management in many markets.

2. Pharmacological Classification and General Purpose

Clopivas is definitively classified as an antiplatelet agent, a category of medicine sometimes referred to as a blood thinner, and is specifically a P2Y12 inhibitor, signifying its precise action on the clotting cascade. The general purpose of this medicine is to support the circulatory system by maintaining smoother blood flow.

The use of Clopidogrel is established for the reduction of thrombotic events, which underscores its crucial role in the overall prevention of blood clot formation in at-risk individuals. It works by permanently modifying a specific receptor on the surface of platelets, thereby inhibiting platelet aggregation.

Regulatory References

  1. NIH DailyMed
  2. MedlinePlus

What side effects are possible with Clopivas?

Possible Side Effects and Safety Information

The safety profile of Clopivas (clopidogrel) is primarily defined by its effects on the blood system and the resulting risk of bleeding. The information below summarizes officially documented safety findings from government regulatory sources.

Primary Safety Concerns

Category Concern
Bleeding Risk Increased risk of bleeding, ranging from common occurrences like bruising and nosebleeds to severe, life-threatening internal hemorrhage (e.g., gastrointestinal or intracranial bleeding).
Serious Blood Disorder Risk of Thrombotic Thrombocytopenic Purpura (TTP), a rare, serious, and sometimes fatal condition characterized by a severe blood disorder.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions include various forms of bleeding, bruising, diarrhea, abdominal pain, and dyspepsia.

Less common and rare reactions, grouped by affected system-organ class, include:

  • Blood and Lymphatic System Disorders: Serious conditions like TTP, agranulocytosis, aplastic anemia, and thrombocytopenia.
  • Nervous System Disorders: Intracranial hemorrhage, headache, and dizziness.
  • Immune System Disorders: Severe hypersensitivity reactions, including anaphylaxis and angioedema.

Safety-Related Restrictions and Limitations

Official regulatory documents note specific conditions where the medicine should not be used (contraindications) or requires caution:

  • Contraindications: Must not be used in patients with active pathological bleeding (e.g., stomach ulcers or internal brain bleeding) or a documented hypersensitivity to the drug.
  • Surgical Procedures: Therapy is generally required to be temporarily stopped (often five days) before elective surgery where there is a major risk of bleeding.
  • Genetic Factors: A regulatory warning notes that individuals identified as CYP2C19 poor metabolizers may have diminished antiplatelet activity, potentially leading to a higher risk of cardiovascular events.
  • Interactions: The use with certain medications, such as some proton pump inhibitors (like omeprazole or esomeprazole), is generally discouraged as they can reduce the drug's intended action.

Overdose and Emergency Response

Overdose and when to seek help

Official government regulatory documents describe the primary manifestation of Clopivas (Clopidogrel) overexposure as prolonged bleeding time, leading to subsequent bleeding complications. The FDA prescribing information notes that acute toxicity studies in non-human subjects resulted in lethal outcomes, with observed signs including vomiting, prostration, and gastrointestinal hemorrhage.

Required Emergency Actions

Immediate medical intervention is required for specific severe symptoms. Government health authority guidance mandates that emergency services (such as 911) must be called immediately if a person who has taken too much medicine exhibits signs of a life-threatening scenario, including collapse, a seizure, trouble breathing, or the inability to be awakened.

Management and Antidote Status

Feature Official Regulatory Statement
Antidote No specific antidote is known for Clopidogrel overdose.
Supportive Measure Platelet transfusion may be considered to restore hemostasis (clotting ability), though efficacy is noted as being potentially reduced if administered too soon after the last dose.
Bleeding Management If bleeding is observed during a suspected overdose, appropriate therapy should be considered, as advised by European regulatory bodies.

In all cases of suspected overdose, contact with the poison control helpline is an officially mandated action.

Therapeutic Uses of Clopivas

What Clopivas Treats: Main Uses and Benefits

Clopivas is commonly used to help with managing conditions associated with heightened physiological stress in at-risk patients. The medicine is applied in addressing conditions involving recurrent or episodic manifestations in patients who have a history of major vascular events like Myocardial Infarction (heart attack), Ischemic Stroke, or Peripheral Arterial Disease (PAD). It is considered relevant for the immediate and ongoing management of Acute Coronary Syndrome, and is relevant for easing symptoms linked to organ-specific functional stress following Coronary Artery Stent placement.

This therapeutic focus means the medicine is applied in clinical settings that involve acute or unstable symptom patterns and supports the patient during difficult episodes by easing distress.

In chronic conditions like PAD, Clopivas may be part of symptomatic management, as it is relevant for easing symptoms linked to organ-specific functional stress, which contributes to improved comfort during periods where symptoms interfere with routine activities.


Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain

It helps manage the risk associated with acute manifestations of reduced blood flow to the heart, and supports the patient during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Clopivas (Clopidogrel) is an antiplatelet medicine officially approved for adult patients with a history of recent myocardial infarction (MI), stroke, or established peripheral arterial disease.

Who Must Not Use Clopivas (Contraindications)

Official regulatory labels explicitly prohibit the use of Clopivas in patients with:

  • Active pathological bleeding, such as an intracranial hemorrhage or peptic ulcer.
  • Severe hepatic impairment (severe liver disease).
  • Hypersensitivity (allergic reaction) to Clopidogrel or any component of the product.

Conditional Use and Restrictions

Population/Condition Regulatory Status Constraint
Pediatric Population (Under 18) Not established / Not recommended Safety and effectiveness have not been established.
Recent Ischemic Stroke Not recommended (first 7 days) Use is not recommended during the initial 7 days due to lack of data.
Renal/Moderate Hepatic Impairment Caution / Limited experience Therapeutic experience is limited; use must be approached with caution.
CYP2C19 Poor Metabolizers Warning / Consider alternative Diminished antiplatelet activity; alternative treatment may be necessary.

For pregnancy, use is advised only if clearly needed. For nursing mothers, regulatory guidance requires a decision to discontinue the drug or discontinue nursing.

What should I know about interactions with other medicines?

Clopidogrel (the active substance in Clopivas) interacts with several other medications through two main mechanisms: affecting the metabolism of clopidogrel itself and increasing the risk of bleeding.

Diminished Effectiveness (Metabolic Interaction)

Clopidogrel is an inactive medicine that must be converted by the liver enzyme CYP2C19 into its active form. Certain drugs interfere with this process, significantly reducing clopidogrel's antiplatelet activity. These include the strong CYP2C19 inhibitors omeprazole and esomeprazole. Their concurrent use should be avoided to ensure clopidogrel remains effective.

Interacting Product Category Specific Examples
CYP2C19 Inhibitors Omeprazole, Esomeprazole
Opioids Morphine (can delay/reduce absorption)

Increased Bleeding Risk (Additive Effect)

Co-administration with other medicines that affect blood clotting or can cause bleeding carries an increased risk of hemorrhage. This is a pharmacodynamic, or additive, effect.

Interacting Product Category Specific Examples
Anticoagulants Warfarin
NSAIDs (Nonsteroidal Anti-inflammatory Drugs) Ibuprofen, Naproxen
SSRIs/SNRIs (Certain Antidepressants) Selective Serotonin Reuptake Inhibitors, Serotonin Norepinephrine Reuptake Inhibitors
Other Antiplatelet Agents (Additive effect)

Other Documented Interactions

Clopidogrel and its metabolites are documented to inhibit the enzyme CYP2C8. This can lead to increased blood concentrations of drugs metabolized by this pathway, such as repaglinide, a medicine for diabetes. In preparation for elective surgery with a high bleeding risk, it is typically recommended to discontinue clopidogrel approximately five days prior to the procedure to allow platelet function to recover.

Mechanism of Action

How Clopivas Works: Mechanism of Action

Clopivas (Clopidogrel) functions as an inactive prodrug that requires activation by specific hepatic enzymes, primarily CYP2 C19, to yield its active metabolite. This active compound targets the P2Y12 receptor located on the surface of blood platelets, forming an irreversible covalent bond that permanently antagonizes the receptor. Blocking the P2Y12 receptor prevents the binding of ADP and halts the subsequent internal signaling cascade.

This molecular inhibition prevents the activation of the GPIIb/ IIIa receptor complex, which is essential for platelets to link together via fibrinogen. This sequence results in a measurable, dose-dependent reduction in the aggregation and stickiness of circulating platelets. Because the binding is irreversible, this peripheral action is sustained, leading to a prolonged bleeding time and a functional alteration of the hemostatic system that persists until new platelets are generated (approximately 7 to 10 days).

Dosage and Administration Information

How to Use Clopivas: Official Administration Guidelines

Clopivas (Clopidogrel) administration is governed by specific protocols which define its route, dosage, and frequency patterns for use in managing cardiovascular risk. The standard form is a film-coated tablet for oral administration, which must be swallowed whole without crushing or splitting.

Official Dosing Regimens

The dosage schedule is dependent upon the patient's condition:

Clinical Condition Administration Schedule Dose Frequency
Established Atherothrombotic Conditions (MI, Stroke, PAD) Maintenance 75 mg Once daily
Acute Coronary Syndrome (ACS) (Unstable Angina/NSTEMI) Loading Dose 300 mg Single administration
Acute Coronary Syndrome (ACS) (Unstable Angina/NSTEMI) Maintenance 75 mg Once daily

For patients 75 years of age and older with ST-Elevation Myocardial Infarction (STEMI), the 300 mg loading dose is generally omitted, and the 75 mg once-daily dose is initiated directly.

Administration Context

Clopivas tablets may be taken with or without food. Administration is required only once daily for the maintenance phase, establishing a low-frequency protocol designed for long-term consistency. If a dose is missed by less than 12 hours from the usual time, it should be taken immediately. If more than 12 hours have passed, the missed dose should be skipped to maintain the once-daily schedule and avoid doubling the subsequent dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clopivas

1. Evidence for Use in Recent Heart Attack (Myocardial Infarction) and Acute Coronary Syndrome

Research has been conducted on Clopivas in adults following a heart attack (MI) or during an Acute Coronary Syndrome (ACS), such as unstable angina. These studies typically involved large, international, Randomized Controlled Trials (RCTs) where groups of patients was observed in a structured setting. The trials monitored outcomes related to systemic or functional imbalance, including measurements of new events such as another heart attack, stroke, or cardiovascular death.

The evidence often involves studies that studied the co-administration of Clopivas alongside aspirin, a combination known as Dual Antiplatelet Therapy (DAPT). A key area of uncertainty in this group relates to genetic factors: research explored the conversion process of the drug within the body, finding that certain genetic variations may mean the body's ability to complete this process is diminished.

2. Evidence for Use Following Ischemic Stroke and TIA (Transient Ischemic Attack)

Clopivas was evaluated in numerous RCTs focusing on adults who experienced a recent ischemic stroke or a Transient Ischemic Attack (TIA). This research explored whether the use of the medicine was associated with the occurrence of a subsequent stroke or heart attack. Research has also studies explored the drug's use as a monotherapy (by itself) over longer periods in comparison to aspirin. While research contextualizes the findings for short-term use following these events, the data for certain groups remain insufficient.

3. Evidence in Special Populations and Unique Patient Groups

Research has explored patterns of outcomes in different demographic groups receiving Clopivas, including older adults. A significant body of research was evaluated in patients based on their genetic makeup, specifically the CYP2C19 enzyme. Findings indicate that for patients who are classified as "poor metabolizers" by this enzyme, the measured outcomes appear to be diminished. Data for certain groups remain insufficient, such as evidence in pediatric populations or pregnant individuals; results apply only to the populations studied and cannot be generalized to these groups.

Key Studies & References

  1. Clopidogrel Therapy and CYP2C19 Genotype (NIH Medical Genetics Summaries)

Frequently Asked Questions (FAQ)

Common questions about Clopivas (FAQ)

Q: Is Clopivas considered a blood thinner, and how is it different from aspirin?

A: Clopivas is classified as an antiplatelet agent, which is a type of medicine sometimes referred to as a blood thinner. It works by blocking a specific receptor (P2Y12) on platelets. Aspirin is also an antiplatelet agent, but it targets a different enzyme. They work through distinct mechanisms, which is why they are sometimes used together in combination therapy to prevent blood clots.


Q: What happens if I accidentally miss a dose of Clopivas?

A: According to official administration guidelines, if a dose is missed by less than 12 hours from the usual time, it should be taken right away. If more than 12 hours have passed, the missed dose should be skipped, and the next dose should be taken at the usual time to maintain the correct once-daily schedule.


Q: Does Clopivas interact with common over-the-counter pain relievers like ibuprofen?

A: Yes, regulatory information indicates that Clopivas interacts with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes common pain relievers like ibuprofen. The concurrent use of Clopivas and NSAIDs, such as ibuprofen, may increase the risk of bleeding, particularly in the digestive tract.


Q: Is Clopivas safe to take for older adults?

A: Clinical experience and official regulatory data show that the standard maintenance dose is generally included in clinical study protocols for older adults. However, the initial treatment protocol may be adjusted for patients aged 75 and older with certain heart conditions, such as omitting the loading dose, as detailed in specific prescribing information.


Q: Can pregnant or breastfeeding women take Clopivas?

A: Official product information advises that the use of Clopivas during pregnancy is recommended only if the benefit clearly outweighs the risk. For nursing mothers, a decision must be made to either discontinue the drug or discontinue nursing, as it is unknown if the medicine passes into breast milk.


Q: What research supports the use of Clopivas for heart disease prevention?

A: Studies and official information indicate that the use of Clopivas is supported by large, international Randomized Controlled Trials (RCTs). This research has shown that it helps reduce the rate of serious events like heart attack and stroke in people with conditions like recent heart attack, stroke, or Acute Coronary Syndrome (ACS).


Q: Is it possible to take Clopivas with an aspirin regimen?

A: Yes. For many major indications, such as following Acute Coronary Syndrome, regulatory data confirms that Clopivas is administered specifically in combination with aspirin. This is a common and established practice known as Dual Antiplatelet Therapy (DAPT).


Q: Is it true that Clopivas can be less effective in some people due to genetics?

A: Yes, official regulatory warnings address this. Clopivas is an inactive prodrug that requires activation by the CYP2C19 liver enzyme. Individuals with certain genetic variations are known as CYP2C19 poor metabolizers, meaning they convert the drug less effectively, which may result in diminished antiplatelet protection.


Q: Can Clopivas be split or crushed, or must it be swallowed whole?

A: The film-coated tablets must always be swallowed whole and should not be crushed or split. The tablet is specifically formulated for oral administration in its intact form.


Q: Does Clopivas have any effect on blood pressure?

A: Official adverse reaction reports and regulatory documents do not commonly list a direct, significant change in blood pressure as a frequent side effect. The primary safety concerns revolve around the increased risk of bleeding and blood disorders.


Q: Are there any specific foods or drinks I should avoid while on Clopivas?

A: The official product label does not list specific foods or drinks to avoid. The drug can be taken with or without food. Certain components, such as grapefruit juice, are known to inhibit enzymes that could theoretically interfere with how the drug is activated, though this is not a universal regulatory warning.


Q: Can Clopivas be taken with vitamins or herbal supplements?

A: Official drug interaction lists primarily focus on prescription medicines, but the product label indicates caution should be exercised with any product that could increase the risk of bleeding. The combination of Clopivas with other substances is an important factor to discuss with a healthcare professional.


Q: Is it normal to feel a bit more tired when starting Clopivas?

A: Excessive tiredness or fatigue is listed among the possible side effects reported by patients in clinical experience. Other effects on the nervous system, such as headache and dizziness, are also noted in official safety information.


Q: What makes Clopivas different from other antiplatelet drugs?

A: Clopivas belongs to the thienopyridine class of antiplatelets. Its main distinguishing feature is that it is an inactive prodrug that must be metabolized by the liver to its active form, and it then binds irreversibly to the P2Y12 receptor on the platelets to stop them from aggregating.


Q: How long does Clopivas stay in your system after stopping the medication?

A: The action of Clopivas on platelets is irreversible and lasts for the entire lifespan of the affected platelet, which is approximately 7 to 10 days. This is why there is typically a waiting period of about five days before major surgery to allow for new, unaffected platelets to be generated.


Q: Does Clopivas interact with alcohol?

A: The official label does not list a direct chemical interaction with alcohol. However, since Clopivas increases the risk of bleeding, particularly in the digestive tract, caution is warranted when consuming alcohol.


Q: Can you stop taking Clopivas suddenly, or does the dose need to be tapered?

A: Official warnings state that the medication should not be stopped suddenly. Premature discontinuation, particularly in those who have had a stent or recent heart event, significantly increases the risk of serious cardiovascular events, such as a heart attack or stroke.


Q: Does Clopivas interact with cholesterol-lowering medications (statins)?

A: Interactions with statin drugs are often complex. While Clopivas may not have clinically significant interactions with certain statins (like atorvastatin), it can affect the function of the CYP2C8 enzyme, which is responsible for metabolizing other medications.


Q: Do children ever take Clopivas?

A: Official regulatory documents state that the safety and effectiveness of Clopivas have not been established in the pediatric population, which includes all individuals under 18 years of age. Therefore, its use is generally not recommended for children.


Q: Can taking Clopivas make me more sensitive to the sun?

A: Skin-related reactions are a documented possibility among the less common side effects. While the regulatory documents may not explicitly list photosensitivity, adverse reactions such as rash and dermatitis are noted.


Q: What kind of monitoring is needed while on Clopivas (blood tests, etc.)?

A: Close monitoring may be necessary due to the small risk of rare, serious blood disorders like Thrombotic Thrombocytopenic Purpura (TTP). If serious conditions are suspected, such as TTP, urgent medical evaluation, including blood tests, would be necessary.


Q: Will Clopivas affect my ability to drive or operate machinery?

A: The regulatory information indicates that Clopivas is generally expected to have no or negligible influence on the ability to drive or operate machinery. However, patients should be cautious if they experience side effects that affect alertness, such as dizziness or headache.


Q: Is Clopivas safe for people who have had stomach ulcers?

A: Clopivas is contraindicated (must not be used) in patients who have active pathological bleeding, which includes a currently active peptic ulcer. The drug must be used with caution in patients with a history of ulcers due to the potential for increased bleeding risk.

How should Clopivas be stored and disposed of?

How to Store and Dispose of Clopivas

Clopivas (clopidogrel) tablets must be stored according to specific regulatory requirements to maintain stability and ensure safety.

Storage Requirements

The medicine should be stored at a controlled room temperature, typically defined as below 30 C (86 F), and must not be frozen. The tablets must be kept in their original container to be protected from light and moisture. This medication must always be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Clopivas must be handled responsibly. The product must not be thrown into household waste or wastewater due to environmental considerations. Patients must dispose of the medication according to local requirements, often by returning it to a pharmacist or using an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clopivas found in:

A-Z Index: